Aaron Qi Yang Goh

Dr. Aaron Qi Yang Goh

MOH Holdings Private Limited, Singapore, Central Singapore, Singapore
orcid

Research Focus & Metrics

Representative Publications

View All Publications
18 September 2021 in Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
Verified
Journal Article
Closed access
PDF file
AGAaron Qi Yang Goh
Aaron Qi Yang Goh
NLNicholas Yong Wai Lo
Nicholas Yong Wai Lo
CDCourtney Davis
Courtney Davis
CCChu Shan Elaine Chew
Chu Shan Elaine Chew

16 April 2021 in Indian Journal of Orthopaedics
Verified
Journal Article
Closed access
PDF file
RMRishi Malhotra
Rishi Malhotra
AGAaron Qi Yang Goh
Aaron Qi Yang Goh
AGAntony W. Gardner
Antony W. Gardner

4 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NKNg Kaiwen
Ng Kaiwen
AGAaron Qi Yang Goh
Aaron Qi Yang Goh
BSBryan Xiangrong Sim
Bryan Xiangrong Sim
SYSri Yudah
Sri Yudah
PCPauline Poh Lin Chan
Pauline Poh Lin Chan
ACAudrey Wei Lin Chia
Audrey Wei Lin Chia
Aim: In this retrospective audit, Atropine 0.025% eyedrops were evaluated in a clinical setting. Method: Children aged 4–16 years, who were started on Atropine 0.025% with at least 6 months of follow-up, were included. A total of 588 eyes (299 children) were classified as treatment-naïve eyes started on Atropine 0.025% daily (Group A, n146), eyes progressing on Atropine 0.01% daily increased to 0.025% daily (Group B, n287) or combined with myopia control glasses (Group C, n66), and those stable on Atropine 0.01% twice daily converted to Atropine 0.025% daily (Group D, n89). Spherical equivalent (SE) and axial length (AL) were recorded from 6 months before treatment to 24 months after treatment began. Result: Group A children were younger (8.4 ± 1.5 years), while Group D children were older (10.6 ± 1.59 years). Progression in the first 6 m was significantly less than that in 6 m prior in Groups A-C. At 1 year, a change in AL < 0.15 mm was noted in 41%, 49%, 50% and 35%, and a change in AL ≥ 0.30 mm was observed in 38%, 18%, 32% and 23% of eyes in Groups A, B, C and D, respectively. Treatment was increased in 37%, 34%, 12% and 41% of eyes over 2 years in Groups A, B, C and D, respectively. Mean progression at 2 years was −0.63 ± 0.86 D or 0.44 ± 0.31 mm, −0.39 ± 0.59 D or 0.30 ± 0.26 mm, −0.30 ± 0.48 D or 0.36 ± 0.40 mm, and −0.48 ± 0.54 D or 0.33 ± 0.22 mm in Groups A, B, C and D, respectively. Multivariate analysis suggested that progression was mainly associated with younger age. Conclusions: Atropine 0.025% was a useful addition to myopia control, with some eyes requiring further modification in treatment.